Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030000, China.
Department of High School, Jinzhong Boya Peiwen Experimental School, Taiyuan, Shanxi, 030000, China.
Sci Rep. 2024 Oct 21;14(1):24701. doi: 10.1038/s41598-024-76158-7.
Prostate cancer is one of the most common cancers in men and poses a significant threat to global male health. Traditional prostate cancer assessment methods have certain limitations, necessitating the identification of new prognostic factors and treatment targets. Our study revealed that low expression of the cornichon family AMPA receptor auxiliary protein 2 (CNIH2) gene was associated with a better progression-free survival rate in prostate cancer patients. The area under the receiver operating characteristic (ROC) curve (AUC) showed that the prognostic ability of the CNIH2 gene was high at 1, 3, and 5 years. The gene was an independent prognostic factor according to multivariate analysis. Functional verification experiments showed that knocking down the CNIH2 gene could inhibit the proliferation, migration and invasion of prostate cancer cells and could also inhibit tumor growth in nude mice. Our study is the first to reveal the important role of the CNIH2 gene in prostate cancer. This discovery provides a new research direction for individualized treatment and prognostic evaluation of prostate cancer.
前列腺癌是男性中最常见的癌症之一，对全球男性健康构成重大威胁。传统的前列腺癌评估方法存在一定的局限性，因此需要寻找新的预后因素和治疗靶点。我们的研究表明，cornichon 家族 AMPA 受体辅助蛋白 2（CNIH2）基因低表达与前列腺癌患者无进展生存率的提高相关。受试者工作特征（ROC）曲线下面积（AUC）显示，CNIH2 基因在 1、3 和 5 年的预后能力较高。根据多因素分析，该基因是一个独立的预后因素。功能验证实验表明，敲低 CNIH2 基因可以抑制前列腺癌细胞的增殖、迁移和侵袭，并且可以抑制裸鼠肿瘤的生长。我们的研究首次揭示了 CNIH2 基因在前列腺癌中的重要作用。这一发现为前列腺癌的个体化治疗和预后评估提供了新的研究方向。
